NLX-112

NLX-112 (befiradol, F13640) is a first-in-class, highly selective and full agonist of the serotonin 5-HT1A receptor. It is being developed as an oral therapy for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. Unlike traditional dopaminergic therapies, NLX-112 targets serotonergic neurons to inhibit their activity via activation of 5-HT1A autoreceptors. This mechanism reduces the unregulated conversion and release of dopamine by serotonin neurons—a key driver of LID—while maintaining antiparkinsonian efficacy. Clinical studies have shown that NLX-112 significantly reduces dyskinesia and improves motor symptoms in people with Parkinson’s disease while being well tolerated[1][2][3][4][5][6][7][8].

Brand names

befiradol

Other names

NLX-112NLX112NLX 112befiradolF13640F-13640F 13640